Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.
This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
The CDC's vaccine policy advisors haven't budged on new RSV guidance, remaining unconvinced that younger adults at higher ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...